Who is sponsoring NCT03563235?

NCT03563235 is sponsored by Fujian Academy of Traditional Chinese Medicine.

What drugs are being tested in NCT03563235?

Interventions in NCT03563235: Xulin Jiangu granules, Calcitriol capsules.

What condition does NCT03563235 study?

NCT03563235 studies Postmenopausal Osteoporoses.

Is NCT03563235 still recruiting?

NCT03563235 is currently status unknown. Last updated 26 February 2019.

Last reviewed 2019-02-26 · How we verify

NCT03563235: CSOPOPWXJG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules

Status unknown EARLY_PHASE1 Last updated 26 February 2019

What this trial tests

EARLY_PHASE1 trial testing Xulin Jiangu granules in Postmenopausal Osteoporoses in 60 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
30 September 2021

31 December 2021

Quick facts

Lead sponsor	Fujian Academy of Traditional Chinese Medicine
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 September 2019
Primary completion	30 September 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Xulin Jiangu granules — full drug profile →
Calcitriol capsules — full drug profile →

Conditions studied

Postmenopausal Osteoporoses — all drugs for Postmenopausal Osteoporoses →

Sponsor

Fujian Academy of Traditional Chinese Medicine — full company profile →

Who can join

Adults 50 to 70, female only, with Postmenopausal Osteoporoses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Osteoporosis is a common senile disease with a high incidence. The Chinese medicine differentiation treatment has small side effects and can be taken for a long time, which has certain advantages. This project adopts the experience of the person in charge of the project-Xulin Jiangu Granules and clinically collects patients with postmenopausal osteoporosis (kidney deficiency and blood stasis syndrome).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Inflammaging-Driven Osteoporosis: Is a Galectin-Targeted Approach Needed?
Russo M, Lepre CC, Itro A, Martin G, et al · · 2025 · cited 1× · PMID 40650248 · DOI 10.3390/ijms26136473

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03563235 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Academy of Traditional Chinese Medicine
Last refreshed: 26 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03563235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing